Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.

被引：0
|
作者：
Eroglu, Zeynep
Kim, Dae Won
Johnson, Douglas Buckner
Algazi, Alain Patrick
Munhoz, Rodrigo Ramella
Liniker, Elizabeth
Kong, Ben
Khurana, Neharika
Chmielowski, Bartosz
Sosman, Jeffrey Alan
Scolyer, Richard A.
Carlino, Matteo S.
Postow, Michael Andrew
Hwu, Wen-Jen
Long, Georgina V.
Ribas, Antoni
机构：
[1] City Hope Natl Med Ctr, Pasadena, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Vanderbilt Univ, Nashville, TN 37235 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Melanoma Inst Australia, Sydney, NSW, Australia
[7] Westmead Canc Ctr, Strathfield, NSW, Australia
[8] UC San Francisco, San Francisco, CA USA
[9] Univ Calif Los Angeles, Los Angeles, CA USA
[10] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[11] Univ Sydney, Melanoma Inst Australia, Royal Prince Alfred Hosp, Sydney, NSW 2006, Australia
[12] Westmead Hosp, Baulkham Hills, Australia
[13] Melanoma Inst Australia, Sydney, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9011
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PERFORMANCE STATUS AS A PREDICTOR OF RESPONSE TO ANTI-PD1 FOR METASTATIC MELANOMA
    Wong, A.
    Williams, M.
    Milne, D.
    Morris, K.
    Lau, P.
    Spruyt, O.
    Fullerton, S.
    McArthur, G.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 71
  • [22] Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma
    Tumeh, Paul Camille
    Rosenblum, Michael
    Handley, Nathan
    Tsai, Katy
    Rodriguez, Robert S. Rodriguez
    Khurana, Niharika
    Harview, Christina
    Spasic, Marko
    Sanchez, Phillip J.
    Chang, Jeremy
    Shintaku, I. Peter
    Taylor, Emma
    Chmielowski, Bartosz
    Grogan, Tristan
    Elashoff, David A.
    Pierce, Robert H.
    Daud, Adil
    CANCER RESEARCH, 2015, 75
  • [23] Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
    Paoluzzi, L.
    Cacavio, A.
    Ghesani, M.
    Karambelkar, A.
    Rapkiewicz, A.
    Weber, J.
    Rosen, G.
    CLINICAL SARCOMA RESEARCH, 2016, 6
  • [24] Checkpoint inhibitors anti PD1/PDL1 in metastatic NSCLC
    Hirsh, Vera
    JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [25] Outcomes after progression of disease with anti-PD-1/PDL1 therapy for advanced melanoma
    Patrinely, James R.
    Wang, Laura X.
    Davis, Elizabeth J.
    Johnson, Douglas B.
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Predict progression free survival and overall survival using objective response rate for anti-PD1/PDL1 therapy development
    Yang, Lei
    Raveendran, Geethanjali
    Meng, Xiang
    Lin, Ji
    Meng, Zhaoling
    BMC CANCER, 2024, 24 (01)
  • [27] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [28] Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC).
    Teo, Min Yuen
    Whiting, Karissa
    Mota, Jose Mauricio
    Li, Han
    Regazzi, Ashley Marie
    Solit, David B.
    Aggen, David Henry
    Lee, Chung-Han
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Toxicity and Survival for Metastatic Melanoma Patients Treated With Anti-PD1 Therapy and Radiation Treatment
    Mowery, Y. M.
    Patel, K.
    Olson, A. C.
    Khan, M. K.
    Salama, J. K.
    Salama, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S158 - S159
  • [30] Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma
    Roncati, Luca
    ACTA DERMATOVENEROLOGICA CROATICA, 2018, 26 (04) : 341 - 343
12345